New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTripeptide-29 vs AOD-9604

Tripeptide-29 vs AOD-9604

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Tripeptide-29
Fat Loss & Metabolic
AOD-9604
Summary
Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
Half-Life
Not applicable (topical)
30-45 minutes injectable; longer with nasal spray formulation
Admin Route
Topical
SubQ, Intranasal, Oral
Research
Typical Dose
0.01-0.1% in formulation
300-600 mcg
Frequency
Once or twice daily
Once daily
Key Benefits
  • Stimulates fibroblast collagen synthesis via damage-signal mechanism
  • Reduces fine lines and improves skin smoothness
  • Supports dermal matrix integrity
  • Naturally bioidentical to collagen fragment sequences
  • Well-tolerated in all skin types
  • Synergistic with copper peptides and retinoids
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
Side Effects
  • Excellent tolerability profile
  • No documented significant adverse effects at cosmetic concentrations
  • Rare sensitivity reactions in individuals with peptide allergies
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
Stacks With